Asia Pacific PoC molecular diagnostics market will grow by 15.1% annually with a total addressable market cap of $8,360.1 million over 2020-2030 owing to the rising adoption of PoC molecular diagnostics for drug discovery and development amid COVID-19 pandemic.
Highlighted with 34 tables and 52 figures, this 124-page report “Asia Pacific Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific PoC molecular diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
In-depth qualitative analyses include identification and investigation of the following aspects:
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific PoC molecular diagnostics market in every aspect of the classification from perspectives of Product, Technology, Application, End User, and Country.
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Polymerase Chain Reaction (PCR)
Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Infectious Disease
Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Geographically, the following national/local markets are fully investigated:
Detailed analysis and 2019-2030 annual revenue are available for each key national market. The breakdown of key national markets by Product, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific PoC molecular diagnostics market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Highlighted with 34 tables and 52 figures, this 124-page report “Asia Pacific Point of Care (PoC) Molecular Diagnostics Market 2020-2030 by Product (Assays, Instruments, Software), Technology (PCR, INAAT, Microarray), Application, End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific PoC molecular diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.
In-depth qualitative analyses include identification and investigation of the following aspects:
- Market Structure
- Growth Drivers
- Restraints and Challenges
- Emerging Product Trends & Market Opportunities
- Porter’s Five Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific PoC molecular diagnostics market in every aspect of the classification from perspectives of Product, Technology, Application, End User, and Country.
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Kits & Assays
- Analyzers & Instruments
- Software & Services
Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Polymerase Chain Reaction (PCR)
- Real-Time PCR (rt-PCR)
- Digital PCR (d-PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Genetic Sequencing-based Technology
- Microarray-based Technology
- Other Technologies
Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Infectious Disease
- Respiratory Infections
- Hospital Acquired Infections
- Sexually Transmitted Infections
- Gastrointestinal Infections
- Oncology
- Hepatitis
- Prenatal/Neonatal Testing
- Other Applications
Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
- Hospitals
- Clinics & Diagnostic Centers
- Research and Academic Institutes
- Other End Users
Geographically, the following national/local markets are fully investigated:
- Japan
- China
- South Korea
- Australia
- India
- Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
Detailed analysis and 2019-2030 annual revenue are available for each key national market. The breakdown of key national markets by Product, Technology, and Application over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Asia Pacific PoC molecular diagnostics market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
- Abacus Diagnostica Oy
- Abbott Laboratories
- Alere Inc.
- Biocartis Group NV
- Biomerieux SA
- Bio-Rad Laboratories Inc
- Danaher Corporation
- DiaSorin S.p.A
- DxNA LLC.
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Luminex Corporation
- Meridian Bioscience Inc.
- Mesa Biotech Inc.
- QIAGEN N.V.
- QuantuMDx Group Ltd.
- Quidel Corporation
- Spartan Biosciences Inc.
- Thermo Fisher Scientific
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Table of Contents
1 Introduction
2 Market Overview and Dynamics
3 Segmentation of Asia Pacific Market by Product
4 Segmentation of Asia Pacific Market by Technology
5 Segmentation of Asia Pacific Market by Application
6 Segmentation of Asia Pacific Market by End User
7 Asia-Pacific Market 2019-2030 by Country
8 Competitive Landscape
9 Investing in Asia Pacific Market: Risk Assessment and Management
List of Tables
List of Figures
Companies Mentioned
A selection of companies mentioned in this report includes:
- Abacus Diagnostica Oy
- Abbott Laboratories
- Alere Inc.
- Biocartis Group NV
- Biomerieux SA
- Bio-Rad Laboratories Inc
- Danaher Corporation
- DiaSorin S.p.A
- DxNA LLC.
- F. Hoffmann-La Roche Ltd.
- Hologic, Inc.
- Luminex Corporation
- Meridian Bioscience Inc.
- Mesa Biotech Inc.
- QIAGEN N.V.
- QuantuMDx Group Ltd.
- Quidel Corporation
- Spartan Biosciences Inc.
- Thermo Fisher Scientific
Methodology
LOADING...